Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciara Metcalfe

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
NPJ Systems Biology and Applications|January 10, 2025
Transformer-based modeling of Clonal Selection and Expression Dynamics reveals resistance mechanisms in breast cancerNathan D Maulding, Jun Zou, Wei Zhou, et al.
Expert Opinion on Investigational Drugs|October 25, 2021
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancerYa-Chi Chen, Jiajie Yu, Ciara Metcalfe, et al.
NPJ Breast Cancer|February 22, 2024
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscapeNayan Chaudhary, Alejandro M Chibly, Ann Collier, et al.
Cancer Research|October 25, 2013
PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibitionCiara Metcalfe, Bruno Alicke, Ailey Crow, et al.
Cancer Research|July 29, 2010
Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancerCiara Metcalfe, Ashraf E K Ibrahim, Michael Graeb, et al.
Molecular Cancer Therapeutics|September 20, 2019
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical ModelsHeather M Moore, Heidi M Savage, Carol O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2025
Clinical Context Shapes the Relationship Between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate CancerKalpit Shah, Matthew H Secrest, Wei Zhou, et al.
BMC Cancer|May 24, 2024
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancerSherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, et al.
Nature Cancer|January 13, 2025
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER<sup>+</sup> breast cancerJackson Liang, Xiaosai Yao, Patrick Aouad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2023
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerSarat Chandarlapaty, Maura N Dickler, Jose Alejandro Perez Fidalgo, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
NPJ Systems Biology and Applications|January 10, 2025
Transformer-based modeling of Clonal Selection and Expression Dynamics reveals resistance mechanisms in breast cancerNathan D Maulding, Jun Zou, Wei Zhou, et al.
Expert Opinion on Investigational Drugs|October 25, 2021
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancerYa-Chi Chen, Jiajie Yu, Ciara Metcalfe, et al.
NPJ Breast Cancer|February 22, 2024
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscapeNayan Chaudhary, Alejandro M Chibly, Ann Collier, et al.
Cancer Research|October 25, 2013
PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibitionCiara Metcalfe, Bruno Alicke, Ailey Crow, et al.
Cancer Research|July 29, 2010
Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancerCiara Metcalfe, Ashraf E K Ibrahim, Michael Graeb, et al.
Molecular Cancer Therapeutics|September 20, 2019
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical ModelsHeather M Moore, Heidi M Savage, Carol O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2025
Clinical Context Shapes the Relationship Between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate CancerKalpit Shah, Matthew H Secrest, Wei Zhou, et al.
BMC Cancer|May 24, 2024
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancerSherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, et al.
Nature Cancer|January 13, 2025
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER<sup>+</sup> breast cancerJackson Liang, Xiaosai Yao, Patrick Aouad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2023
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerSarat Chandarlapaty, Maura N Dickler, Jose Alejandro Perez Fidalgo, et al.
Pageof 4